Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diclofenac + betamethasone is a combination drug consisting of two active pharmaceutical ingredients: - Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), which works by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins involved in pain and inflammation. - Betamethasone, a potent synthetic glucocorticoid corticosteroid that exerts anti-inflammatory and immunosuppressive effects by modulating gene expression through the glucocorticoid receptor. This combination is primarily formulated as a topical preparation for the treatment of various inflammatory skin conditions. The rationale for combining these agents is to provide enhanced anti-inflammatory action via complementary mechanisms—diclofenac targeting prostaglandin-mediated pathways and betamethasone suppressing broader inflammatory responses. The combination may also be used off-label or in compounded formulations for other indications where both NSAID and corticosteroid actions are desired[4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diclofenac + betamethasone.